Consumer Healthcare

Studies on consumer trials that accelerates consumer

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Consumer Healthcare.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Category Alerts


Bayer sells the drug Nebido to Gr?nenthal in a $500 million deal.

August 09, 2022
alert level: Medium

Swanson Health Launches Swanson W/I/O?

August 10, 2022
alert level: Medium

Haleon emerges from GSK consumer healthcare spin-off

July 28, 2022
alert level: Medium

Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Consumer Healthcare

Consumer Healthcare Market Monitoring Dashboard

Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Consumer Healthcare Industry Benchmarks

Savings Achieved

(in %)

The average annual savings achieved in Consumer Healthcare category is 5.40%

Payment Terms

(in days)

The industry average payment terms in Consumer Healthcare category for the current quarter is 73.4 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length


Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk



Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Consumer Healthcare Suppliers

    Total Suppliers
    Diverse Suppliers
    Normalized Supplier Rating
    Consumer Healthcare Supplier

    Find the right-fit consumer healthcare supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Jackson, Mississipi
    Duns number

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance

    Limited (1)
    ESG Perfomance (/100)
    6 Domains Performance (/100)
    Business behaviour
    Human rights
    Community Environment
    Corporate governance
    Human resources
    Security Scorecard

    Threat indicators
    Network Security
    Detecting insecure network settings
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    Application Security
    Detecting common website application vulnerbilities
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    Industry average
    Adverse Media Appearances
    Environmental Issues
    Workforce Health Safety Issues
    Product Service Issues
    Human Rights Issues
    Production Supply Chain Issues
    Environmental Non Compliance Flags
    Corruption Issues
    Regulatory Non Compliance Flags
    Fraud Issues
    Labor Health Safety Flags
    Regulatory Issues
    Workforce Disputes
    esg energy transition
    Discrimination Workforce Rights Issues
    esg controversies critical severity

    Consumer Healthcare market frequently asked questions

    As per Beroe's analysis, the consumer healthcare market size of different continents like North America, Europe, Asia Pacific, and Latin America is $266.59 Bn, $208.95 Bn, $144.10 Bn, and $100.87 Bn respectively.

    Consumers suffering from mild gastrointestinal conditions usually rely on drugs like laxatives, antidiarrheals, and digestives.

    The practice of self-medication reduces the pressure on medical services and patients living in rural areas can easily access it. Further, it will also positively affect the market beyond 2020.

    As per the insights from Beroe's report, the key suppliers of the consumer healthcare market are: Myoderm Piramal Healthcare Catalent Inc. Quantex Recipharm ABCO Laboratories, Inc. Zeon Lifesciences North Carolina Clinical Research Novex Clinical Research Covance

    From Beroe's report, one can conclude that the US and Europe are the major markets for consumer healthcare products, whereas, APAC is growing rapidly at a CAGR of 18 percent.

    As per the consumer healthcare market report shared by Beroe, the volume-based model is the most preferred model in the consumer healthcare market, while the service-based model is alternatively preferred by the consumers. Similarly, the FTE model is more preferred when it comes to pricing, while FFS and fixed-unit price are alternate models prevalent within the consumer healthcare market.

    Following the data from Beroe's report, with a shift in buyer trend and increasing outsourcing of consumer healthcare services, the suppliers are expanding their capacities. Similarly, strategic partnerships between CROs and big consumer healthcare companies will drive flexibility, reduce costs, and extend expertise.

    As per Beroe's report, the following are the main drivers of the consumer healthcare market: Increasing use of online resources and e-commerce websites Self-medication Aging population Focus on wellness

    The following three constraints are prevalent within the market: Increasing regulatory framework across the regions Prevention of abuse and misuse by the consumers Counterfeiting prevention

    As per the global consumer healthcare market, the availability of low-cost drugs to the public is the main driving force for the emerging consumer healthcare market.

    Consumer Healthcare market report transcript

    Global Market Outlook on Consumer Healthcare Services

    • Consumer health products do not require a written prescription from healthcare professionals but can be purchased directly from a pharmacy store
    • Factors like the increasing use of online resources and e-commerce websites will aid the prospects for consumer healthcare market size growth
    • For instance, websites such as,, and offer a wide array of vitamin health drinks, protein shakes, and supplements online. Also, these sites offer live interactive chat sessions to provide instant support to individuals who face challenges while purchasing such products
    • This recent shift toward the use of e-commerce websites and online resources is expected to drive the market growth for consumer healthcare products during the forecast period

    Consumer Healthcare Industry Analysis

    Regional Market Analysis

    North America and Europe

    • Major pharmaceutical, consumer products, medical device manufacturing companies, CRAMS organizations and health insurance companies are located here. In September 2016, the Senate Committee announced the need to explore FDA's mandates on safety of cosmetics, and if the current regulations are in par to provide 100 percent consumer safety and has been issuing regulations on various consumer products relating to chemical poisoning, manufacturing practices and its impact on consumer health
    • The European Commission's (EC) Chemical regulation body, European Chemicals Agency (ECHA) is focused on testing and evaluation of chemicals and entities under REACH, to evaluate the effect of these substance on people and aims to fill and update the gaps in dossiers to improve the data quality


    • Since the former ‘Pharmaceutical Affairs Act' unified manufacturing and sales in Japan until 2005, Japan was not fertile soil for CMOs to develop. Once manufacturing and sales were recognized as separate by the ‘ Revised Pharmaceutical Affairs Act' , the Japanese CRO/CMO market has been growing ever

    Asia Pacific

    • Due to the lower cost of manufacturing and labor, with a large number of GMP facilities, less regulatory complications, Asia Pacific is growing rapidly
    • China has approved and paved way for a series of GMO crops. Seed companies have complained that china's regulatory process is slow and this news means there is a hope for the companies to expand and gain access to markets


    • Latin America drives the market, as most of the Consumer Healthcare Products Manufacturer's are trying to penetrate the growing market by localizing the products
    • Couple of A&Ms are also taking place in this region among CRAMS & Consumer Healthcare. There is not much growth in other regions, like Africa and the Middle East

    Outsourcing Adoption Rate

    Companies are looking for ways to reduce costs, to overcome capacity constraints, to minimize fixed costs, minimize product-market cycle times and to achieve capital efficiency. Further, these companies are extending their global foot prints and try to localize their products. These companies, therefore, are turning to value-based outsourcing and becoming ‘Consumer Centric’. Key Outsourcing Consumer Healthcare MarketTrends

    • Increasing R&D Failures
    • Capital Efficiency (30-50 percent Cost Optimization)
    • Global Footprints and Localization
    • Capacity Constraints for product & line extensions and new products
    • New Product Development & Delivery Systems Technologies for product differentiation
    • Value added generics
    • Emerging Markets
    • Need for operational excellence in terms of GMP and regulatory compliance
    • Need for integrated & specialty services
    • Need for cost efficiencies due to patent expirations and increasing generics competition
    • Access to proprietary technologies for achieving product differentiation

    Regulatory Trends

    Regulatory paradigms that are evolving at regional level and changing worldwide

    • Evolving of defined and transparent regulatory guidelines for prescription, OTC, dietary supplements, nutritional products etc
    • Regulatory frame work for controlling each & every function research, manufacturing, quality control, labeling, packaging, storage and distribution, logistics etc.
    • Regulatory framework for proof of efficacy and safety
    • Restrictions on animal testing
    • Restrictions on the usage of certain packaging components like plastics for liquids
    • Post-marketing vigilance onthe efficacy & safety
    • Anti-counterfeiting measures throughout the ‘supply chain management

    Growth Drivers and Constraints

    The availability of low cost drugs to the public is a driving force for the emerging consumer healthcare market.


    • Entry of CPG Companies
    • Need for cost efficiencies due to patent expirations and increasing generics competition
    • Access to proprietary technologies for achieving product differentiation
    • Leverage of external R&D sources between companies and service providers
    • Value-based-payment Models
    • Entry of numerous small, virtual start-ups having little market that have no manufacturing capacity and product development experience.
    • Government Policies to provide ‘Affordable Healthcare & Easy Access to Healthcare'


    • Increasing ‘Regulatory Framework' across the regions.
    • Burden of proof w.r.t. health benefit claims and safety esp. in EU
    • Prevention of abuse and misuse by the consumers
    • Counterfeiting Prevention
    • A&M of Vendors with Global CMO Companies thereby minimizing business opportunities and affecting Consumer Healthcare Market-R&D

    Market Trends

    The consumer healthcare market remains highly competitive and fragmented albeit leading companies continuing to consolidate their market position through high-profile and strategic acquisitions.

    • A positive regulatory outlook in key markets, due to new initiatives and frameworks looking to facilitate OTC approvals, will also prompt companies to seek access to new markets.
    • Drug manufacturers, regulators, and consumers are increasing pressure on pharma companies to make the Rx-to-OTC switch, as non-prescription medications are cheaper and easier to access.
    • Beyond basic efficacy data, potential benefits of a switch could include increased access to treatment options, improved quality of life, improved public health, enhanced consumer awareness and involvement, or greater worker productivity
    • An increasing interest in self-medication in both developed and developing countries has been identified as a major contributor to market growth in recent years
    • M&A is expected to remain very active in the coming years fueled by strategic long-term commercial priorities, as companies look to increase revenues through expanded product portfolios.
    • The industry is adapting to a value driven portfolio compared to volume-based approach focusing on benefits over price premium, capitalizing on consumers’ informed peer driven choices.
    • This has put global players in a situation to meet fast emerging consumer needs while maintaining the quality in a continuously evolving global regulatory landscape